Document Detail

Relative bioavailability of levodropropizine 60 mg capsule and syrup formulations in healthy male Korean volunteers: a singledose, randomized-sequence, open-label, two-way crossover study.
MedLine Citation:
PMID:  23351597     Owner:  NLM     Status:  In-Data-Review    
Background: Levodropropizine is an oral non-opioid anti-tussive drug used in treatment of cough. A new generic 60 mg capsule formulation of levodropropizine has recently been developed. Objectives: The aim of this study was to assess the pharmacokinetics and bioequivalence of the test (capsule) formulation and reference (syrup) formulation of levodropropizine (60 mg) in healthy, fasted, male Korean volunteers. Methods: This was a single-dose, randomized sequence, open-label, 2-period crossover study conducted in healthy male Korean volunteers in the fasted state at Kyung Hee University Medical Center (Seoul, Republic of Korea). A single oral dose of the test or reference formulation was followed by a 1-week washout period, after which subjects received the alternative formulation. Blood samples were collected at 0 (predose), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after study drug administration. Plasma concentration of levodropropizine was determined using a validated liquid chromatography tandem mass spectrometry (LCMS/ MS) method. The formulations were considered bioequivalent if the 90% CIs for Cmax, AUC0-12h and AUC0-∞ were within the predetermined bioequivalence range (80 - 125%, according to the guidelines of the Korea Food and Drug Administration (Korea FDA)). Tolerability was evaluated throughout the study based on vital sign measurements, laboratory analysis (blood biochemistry, hematology, hepatic function and urinalysis) and subject interviews concerning adverse events (AEs). Results: A total of 36 male Korean subjects (mean (SD) age, 23.9 (2.4) years (range 19 - 30 years); height, 176.2 (6.1) cm (range 161 - 190 cm); weight, 69.8 (9.1) kg (range 54.0 - 92.2 kg); body mass index, 22.4 (2.1) kg/m2 (range 19.1 - 28.3 kg/m2)) was enrolled and completed the study. The mean values for Cmax, tmax, AUC0-12h, and AUC>sub>0-∞ with the test formulation of levodropropizine were 331.51 ng/ml, 0.60 hours, 784.32 ng×h/ml, and 825.82 ng×h/ml, respectively; for the reference formulation, the values were 332.81 ng/ml, 0.44 hours, 726.46 ng×h/ml, and 769.46 ng×h/ ml, respectively. The 90% CIs for the logtransformed ratios of Cmax (92.74 - 111.24), AUC0-12h (104.31 - 113.67) and AUC0-∞ (103.87 - 113.57) were within the predetermined range for the assumption of bioequivalence. No serious adverse events were reported. Conclusions: This single-dose (60 mg) study found that the test (capsule) and reference (syrup) formulations of levodropropizine met the regulatory criterion for assuming bioequivalence in these healthy, fasted, male Korean subjects. Both formulations were well tolerated in the population studied. Korea FDA registration number: BED-1784.
Jae-Won Jang; Ji-Hyung Seo; Min-Ho Jo; Young-Joo Lee; Young-Wuk Cho; Sung-Vin Yim; Kyung-Tae Lee
Related Documents :
2731977 - Comparison of the reactivities and immunogenicities of procholeragenoid and the b subun...
23669567 - Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of a...
23433097 - Effects of donepezil 23 mg on severe impairment battery domains in patients with modera...
25089947 - Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
1002007 - Combined administration of low dose heparin and aspirin as prophylaxis of deep vein thr...
11153157 - Transfer of interferon alfa into human breast milk.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  51     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  152-60     Citation Subset:  IM    
Department of Pharmaceutical Biochemistry, Department of Life and Nanopharmaceutical Science, College of Pharmacy, Department of Biomedical Science, Department of Clinical Pharmacology, College of Medical Science, Kyung Hee University, and Kyung Hee Drug Analysis Center, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the safety and efficacy of warfarin in Taiwanese patients.
Next Document:  Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teac...